Literature DB >> 8036832

Protection against turkey rhinotracheitis pneumovirus (TRTV) induced by a fowlpox virus recombinant expressing the TRTV fusion glycoprotein (F).

Y Qingzhong1, T Barrett, T D Brown, J K Cook, P Green, M A Skinner, D Cavanagh.   

Abstract

A recombinant fowlpox virus was produced which expressed the fusion protein (F) of turkey rhinotracheitis virus (TRTV), a pneumovirus. Turkey poults were vaccinated twice, at an interval of 2 weeks, intramuscularly and by wing web on each occasion, with the recombinant or a control fowlpox virus. Two weeks after the second vaccination the poults were challenged superconjunctivally and intranasally with virulent TRTV. A partially protective immune response was achieved; turkeys vaccinated with the F recombinant showed milder clinical signs and 1000-fold less challenge virus was recovered from the nose and trachea compared with turkeys that had been vaccinated with control fowlpox virus. Expression of the F protein induced antibodies which were detectable both by an ELISA and a virus neutralization test. These results show that the immune responses to the F protein play a major role in protection against TRTV and indicate that recombinant viruses expressing the TRTV F protein have potential as vaccines against TRT.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8036832     DOI: 10.1016/0264-410x(94)90319-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.

Authors:  M Wang; V Bronte; P W Chen; L Gritz; D Panicali; S A Rosenberg; N P Restifo
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

2.  Recognition of bovine respiratory syncytial virus proteins by bovine CD8+ T lymphocytes.

Authors:  Ruth M Gaddum; Roy S Cook; Julie M Furze; Shirley A Ellis; Geraldine Taylor
Journal:  Immunology       Date:  2003-02       Impact factor: 7.397

3.  Different levels of immunogenicity of two strains of Fowlpox virus as recombinant vaccine vectors eliciting T-cell responses in heterologous prime-boost vaccination strategies.

Authors:  Matthew G Cottingham; Andre van Maurik; Manola Zago; Angela T Newton; Richard J Anderson; M Keith Howard; Jörg Schneider; Michael A Skinner
Journal:  Clin Vaccine Immunol       Date:  2006-07

4.  Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.

Authors:  Rosalind Rowland; Ansar A Pathan; Iman Satti; Ian D Poulton; Magali M L Matsumiya; Megan Whittaker; Angela M Minassian; Geraldine A O'Hara; Matthew Hamill; Janet T Scott; Stephanie A Harris; Hazel C Poyntz; Cynthia Bateman; Joel Meyer; Nicola Williams; Sarah C Gilbert; Alison M Lawrie; Adrian V S Hill; Helen McShane
Journal:  Hum Vaccin Immunother       Date:  2012-11-10       Impact factor: 3.452

5.  Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.

Authors:  Simon H Bridge; Sally A Sharpe; Mike J Dennis; Stuart D Dowall; Brian Getty; Donald S Anson; Michael A Skinner; James P Stewart; Tom J Blanchard
Journal:  Virol J       Date:  2011-09-07       Impact factor: 4.099

Review 6.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

7.  Engineered Newcastle disease virus expressing the F and G proteins of AMPV-C confers protection against challenges in turkeys.

Authors:  Haixia Hu; Jason P Roth; Laszlo Zsak; Qingzhong Yu
Journal:  Sci Rep       Date:  2017-06-22       Impact factor: 4.379

8.  Negligible effect of chicken cytokine IL-12 integration into recombinant fowlpox viruses expressing avian influenza virus neuraminidase N1 on host cellular immune responses.

Authors:  Nadzreeq Nor Majid; Abdul Rahman Omar; Abdul Razak Mariatulqabtiah
Journal:  J Gen Virol       Date:  2020-07       Impact factor: 3.891

Review 9.  Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems.

Authors:  Alejandro Brun; Emmanuel Albina; Tom Barret; David A G Chapman; Markus Czub; Linda K Dixon; Günther M Keil; Bernard Klonjkowski; Marie-Frédérique Le Potier; Geneviève Libeau; Javier Ortego; Jennifer Richardson; Haru-H Takamatsu
Journal:  Vaccine       Date:  2008-12-02       Impact factor: 3.641

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.